Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.
Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. We conducted a retr…